State Street (FDMT) discloses 5.3% holdings — 2.7M shares reported on 03/31/2026

Rhea-AI Filing Summary

4D Molecular Therapeutics Inc ownership filing shows State Street Corporation beneficially owns 2,707,875 shares of common stock, representing 5.3% of the class as of 03/31/2026. The filing lists shared voting power of 2,647,452 and shared dispositive power of 2,707,875 held through affiliated investment-adviser entities.

The report identifies SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company as relevant subsidiaries or advisory holders. The form is a Schedule 13G disclosure of beneficial ownership and is signed by an authorized officer on behalf of State Street.

Insights

Institutional Ownership Analyst

State Street discloses a passive >5% stake in 4D Molecular Therapeutics.

State Street Corporation reports beneficial ownership of 2,707,875 shares of common stock, equal to 5.3% as of 03/31/2026. The position is shown with shared voting and dispositive powers via affiliated asset-management entities.

Filing classifies holdings under investment-adviser subsidiaries (SSGA Funds Management, State Street Global Advisors Europe Limited, State Street Global Advisors Trust Company). Cash-flow treatment and intent (passive vs. active) are indicated by the Schedule 13G classification; subsequent filings could change disclosures if ownership or voting arrangements change.

Corporate Governance Specialist

Report signals standard institutional disclosure rather than corporate control actions.

The submission lists shared voting power 2,647,452 and shared dispositive power 2,707,875, implying voting and disposition are exercised through pooled/advisory arrangements. The filing names specific advisory subsidiaries responsible for the position.

Because this is a Schedule 13G, the position is presented as passive under the filing rules. Any change in status (to active) would require an amended filing that updates classification and timing.

Key Figures

Report date: 03/31/2026 Shares beneficially owned: 2,707,875 shares Percent of class: 5.3% +3 more

6 metrics

Report date 03/31/2026 ownership reported as of this date

Shares beneficially owned 2,707,875 shares Amount beneficially owned reported on Schedule 13G

Percent of class 5.3% Percent of common stock beneficially owned

Shared voting power 2,647,452 shares Shared power to vote or direct the vote

Shared dispositive power 2,707,875 shares Shared power to dispose or direct disposition

CUSIP 35104E100 Identifier for 4D Molecular Therapeutics common stock

Key Terms

Schedule 13G, Beneficially owned, Shared dispositive power

3 terms

Schedule 13G regulatory

"Item 1. Name of issuer: 4D MOLECULAR THERAPEUTICS INC"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficially owned financial

"Item 4. Ownership (a) Amount beneficially owned: 2707875.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Shared dispositive power financial

"Item 4. (iv) Shared power to dispose or to direct the disposition of: 2,707,875"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 09:42 AM Learn about SEC filing dates

FAQ

What stake does State Street (FDMT) report owning?

State Street reports beneficial ownership of 2,707,875 shares, or 5.3% of common stock. The figure is reported as of 03/31/2026 with shared voting power of 2,647,452 and shared dispositive power of 2,707,875 through affiliated investment-adviser entities.

Which State Street affiliates hold the FDMT position?

The filing names SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; and State Street Global Advisors Trust Company. These affiliates are listed as the subsidiaries or advisory entities through which the beneficial ownership is reported on the Schedule 13G.

What does Schedule 13G mean for FDMT shareholders?

A Schedule 13G indicates a passive disclosure of beneficial ownership above 5%. It shows institutional holdings and voting/dispositive powers via advisers; it does not by itself indicate an intent to control or change company governance.

As of what date is the 5.3% ownership reported?

The ownership percentage and share count are reported as of 03/31/2026. The filing bears a signature date of 05/12/2026, which reflects when the Schedule 13G was signed by an authorized officer on behalf of State Street.

Does the filing state whether proceeds or transactions occurred?

The Schedule 13G lists beneficial ownership and voting/dispositive powers but does not describe any sale proceeds or transactional consideration. It attributes holdings to advisory entities; cash-flow treatment is not detailed in the reported ownership lines.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

4D MOLECULAR THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

35104E100

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 35104E100

1

Names of Reporting Persons

STATE STREET CORPORATION

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,647,452.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,707,875.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,707,875.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: 4D MOLECULAR THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 5858 HORTON STREET SUITE 455, EMERYVILLE, CALIFORNIA, 94608
Item 2.
(a)	Name of person filing: STATE STREET CORPORATION;
(b)	Address or principal business office or, if none, residence: ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
(c)	Citizenship: MA
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 35104E100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2707875.00
(b)	Percent of class: 5.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 2,647,452
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 2,707,875
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. NOT APPLICABLE
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. NOT APPLICABLE
Item 9.	Notice of Dissolution of Group.
	Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. NOT APPLICABLE

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

STATE STREET CORPORATION

Signature:	ELIZABETH SCHAEFER
Name/Title:	SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
Date:	05/12/2026